ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
Latest Information Update: 27 Mar 2023
Price :
$35 *
At a glance
- Drugs Evorpacept (Primary) ; Paclitaxel (Primary) ; Trastuzumab-deruxtecan (Primary) ; Trastuzumab-duocarmazine (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Male breast cancer; Oesophageal cancer; Ovarian cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ISPY-P1 Trial; ISPY-P1.01
- Sponsors Quantum Leap Healthcare Collaborative
- 22 Mar 2023 Planned End Date changed from 1 Dec 2022 to 17 Nov 2021.
- 22 Mar 2023 Planned primary completion date changed from 1 Dec 2022 to 17 Nov 2021.
- 22 Mar 2023 Status changed from recruiting to withdrawn prior to enrolment.